VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
VERTEX PHARMACEUTICALS INC / MA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$501.95+2.21 (+0.44%)
Close on Oct 19, 2026
- Market cap
- $128.10B
- P/E (TTM)
- 29.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
86.2%−1.9 pts over 5 years
Operating margin
34.8%−11.3 pts over 5 years
Net margin
32.9%−10.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.9% | +10.4% | +14.1% | +27.8% | |
| Gross profit | +9.1% | +9.7% | +13.6% | +27.5% | |
| Operating income | – | -1.0% | +7.9% | – | |
| Net income | – | +6.0% | +7.8% | – | |
| EPS, diluted | – | +6.1% | +8.3% | – | |
| Free cash flow | – | -6.6% | +1.3% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -10.7% | 36.7% | 22.5% | |
| Return on assets | -4.2% | 27.0% | 16.4% | |
| Current ratio | 2.31 | 4.33 | 2.90 | |
| Interest coverage | – | 49.1× | 313.8× | |
| Inventory turnover | 3.1× | 3.3× | 1.1× | |
| Capex to revenue | 3.3% | 4.2% | 3.6% | |
| Diluted shares | 245M | 263M | 258M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vertex Pharmaceuticals Inc / Ma generated $14.43B from operations and spent $6.42B on capital expenditure, dividends and share buybacks. 21% of that went back into the business.
Generated
$14.43B
Used
$6.42B
Capital expenditure$1.38B21%Dividends$00%Share buybacks$5.05B79%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin32.9%
×Asset turnover0.50×
×Equity multiplier1.37×
=Return on equity, FY202522.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 32.9% | 0.50× | 1.37× | 22.5% |
| FY2024 | -4.9% | 0.49× | 1.33× | -3.2% |
| FY2023 | 36.7% | 0.48× | 1.30× | 23.0% |
| FY2022 | 37.2% | 0.57× | 1.32× | 27.7% |
| FY2021 | 30.9% | 0.60× | 1.34× | 24.9% |
| FY2020 | 43.7% | 0.62× | 1.36× | 36.7% |
| FY2019 | 28.3% | 0.57× | 1.38× | 22.4% |
| FY2018 | 68.8% | 0.62× | 1.51× | 64.9% |
| FY2017 | 10.6% | 0.77× | 2.02× | 16.5% |
| FY2016 | -6.6% | 0.63× | 2.57× | -10.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$3.95B
- Cash generatingOperating cash flow above zero$3.63B
- Return on assets improvedROA up on the prior year-2.4% → 17.5%
- Earnings backed by cashOperating cash flow above net income$3.63B vs $3.95B
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.69 → 2.90
- No dilutionShare count did not rise258M → 258M
- Gross margin improvedGross margin up on the prior year86.11% → 86.24%
- More efficientAsset turnover rose0.48 → 0.53